RE:Time for growth cowards won't give forward guidance. Instead, use weasel words in MD&A:
"Ceapro’s quarterly sales and results primarily fluctuate due to variations in the timing of customer orders, different product mixes, and changes in the capacity to manufacture products."
Retiredceo2016 wrote:
Could 2nd quarter (June 2022) revenue match 1st quarter (March 2022)? If so, profit grows with revenue growth! Stock price easily over $1.00 based on the release of 2nd quarter financials in the next few weeks. Upon release of year-end audited financials can we see a $5 stock price?
I also see a nice premium in the stock price, if Ceapro were to be taken over in the next year. However, is a take over in the best interests of long term stock holders? Ceapro’s equity is $29 million vs. long-term debt of $2.6 million. Based on the recent financials; Ceapro can handle increased debt. Should Ceapro increase debt to provide the company with the capital needed to more aggressively increase revenue/earnings?
I trust the Board is discussing the options for capital! I support the Board in directing management to build a plan for aggressive growth & increased debt……..